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Introduction 
The treatment of benign prostatic hyperplasia (BPH) depends on how pronounced the lower urinary 
tract symptoms (LUTS) are and if they are effecting the quality of life of the patient.  Treatment 
interventions include surgery, pharmacological treatment and lifestyle measures – all of which can 
have an overall positive effect. In addition to this, it is appropriate to consider “watchful waiting” 
where patients are closely monitored to ensure that their condition is stable and an intervention is 
made at an appropriate point, should it be required. This approach has been shown to be safe and 
acceptable to patients.1 
Lifestyle Changes 
For patients who have less troublesome (IPSS<7) symptoms there is an option to employ “watchful 
waiting” in combination with practical advice, which may help to reduce the impact of LUTS. Clearly, 
careful thought around the consumption of fluids with regard to volume and timing may minimise 
the impact of nocturia. In addition, avoidance of caffeinated beverages and spicy foods may be of 
some benefit. 
Pharmacists should be aware of concomitant medication and the potential for it to adversely affect 
the patient’s LUTS; for example, the use and timing of diuretics is an important consideration. Other 
drugs such as decongestants, antihistamines and antidepressants may also complicate symptoms.     
Use of pads or containment products may also be helpful, but in terms of patient acceptability they 
may be less desirable. Such measures are less likely to be effective for patients who have a 
significant degree of outlet obstruction.   
Pharmacological Treatment 
The aim of pharmacological intervention is to reduce bladder and prostate smooth muscle tone or to 
alter the size of the prostate and thus reduce resistance to flow of urine.  
Alpha-adrenoceptor antagonists 
The bladder neck and prostate contains numerous α1- and α2-adrenoceptors within the smooth 
muscle tissue, with preponderance of the α1 subtype. Drugs which act as antagonists at these 
receptors have been shown to improve urinary flow. Older drugs which antagonised both α1 and α2-
adrenoceptors caused significant side effects due to the antagonism of α2 receptors within the 
cardiovascular system. Newer drugs have a higher relative affinity for α1 receptors and are therefore 
associated with less cardiovascular side effects. The drugs currently prescribed for BPH include 
tamsulosin, terazosin, alfuzosin and doxazosin. Most are available as convenient once daily, 
controlled-release preparations. In general, there appears to be little difference in terms of overall 
efficacy with a 2-3mL/s increase in maximum urinary flow rate and improvement in other LUTS 
symptoms and subsequent IPSS score.2 As the action of alpha-adrenoceptor antagonists is restricted 
to alteration in muscle tone there is no decrease in prostate size or subsequent rate of growth. In 
addition, there is no fall in PSA and it has been observed that patients prescribed alpha-
adrenoceptor antagonists show no reduction in terms of the necessity to have surgery at some point 
in the disease progression.3 NICEguidance for the management of lower urinary tract symptoms in 
men4 recommends that alpha-adrenoceptor antagonists be prescribed with moderate to severe 
LUTS and that patients should be reviewed after 4-6 weeks of starting therapy, and then annually 
thereafter. Around 15% of patients5 will experience mild side-effects including headache, dizziness, 
drowsiness and postural hypotension. Patients should be counselled in terms of the likelihood of 
first-dose hypotension and that the first does is best taken where they retire to bed and should 
symptoms such as dizziness, fatigue or sweating occur that they remain lying down until they 
resolve.6 Some men may experience problems with retrograde ejaculation in association with these 
drugs. The decision around which specific agent to use should be made with regard to patient co-
morbidities and tolerance. 
Tamsulosin is licensed for ‘over the counter’ sale within pharmacies for treatment of functional 
symptoms of BPH in males aged 45 to 75 years. It is available as a 400 microgram modified release 
capsule and can be taken for up to six weeks before the patient must be assessed by a G.P. Any 
patient whose symptoms have not improved, or have worsened within 14 days of starting treatment 
should be referred for assessment by their general practitioner. Community pharmacists should be 
fully aware of the complexity of management in this area particularly in the context of the 
differential between BPH and prostatic carcinoma. In addition, it is an excellent opportunity for men 
to discuss LUTS with a health professional where they may otherwise not consider going to see their 
GP. Many men see problems with their urinary tract as an inevitable consequence of getting older, 
and whilst that this may partially be true it can be managed in a constructive way which may have 
less impact on the patient’s quality of life if appropriate medical intervention is sought.   
5α-reductase inhibitors (5ARIs) 
The 5ARIs are indicated for men with LUTS, significantly enlarged prostate glands or those with a 
high PSA >1.4ng/mL and a high likelihood of progression of the condition.4  
Testosterone is converted to dihydrotestosterone (DHT) by the enzyme 5α-reductase in the normal 
process of androgen metabolism. This exists as two isoenzymes, 5α-reductase I and II with 
isoenzyme II being the most plentiful within the prostate.  DHT is significantly more potent than 
testosterone and is one of the driving factors in normal and abnormal prostatic growth. The 5ARIs 
inhibit this conversion and thus have a beneficial effect upon BPH and LUTS.  
There are two 5ARIs licensed for the treatment of BPH; finasteride and dutasteride. Finasteride is a 
Type II 5α-reductase inhibitor and, as such, is less effective at reducing the overall serum 
concentration of DHT when compared to dutasteride, which inhibits both Types I and II.  Both drugs 
significantly reduce serum DHT levels; reductions in prostate volume of 20-30% have been observed 
as has a an improvement on the IPSS scale (typically 3-4.5 points) and an increase in maximum 
urinary flow (typically 1.5-2.5 mL/s) of.7 These effects are generally seen within 3-6 months of 
commencing treatment and persist for a significant duration.  Both drugs also reduce the risk of the 
development of acute urinary retention (AUR) and the need for surgery in comparison to placebo.8, 9 
In addition, both 5ARIs cause reductions in PSA; as such it is likely that the PSA reference range, in 
the context of prostate cancer detection, be reconsidered for patients taking 5ARIs.  
The side effect profile of these drugs is primarily concerned with sexual function, which is predicted 
from the mechanism of action, with patients experiencing loss of libido, erectile and ejaculatory 
dysfunction. Some men may also experience breast tenderness. It should be noted that both drugs 
are present in semen and this could be an issue if the patient’s partner is pregnant or likely to 
become pregnant. In such cases patients should be advised to use a condom to prevent the potential 
for the woman to absorb the drug. Women should also be advised to avoid handling broken tablets 
of finasteride or leaking capsules of dutasteride for the same reasons.   
Initially, patients taking 5ARIs should be reviewed at 3-6 months and thereafter every 6-12 months.  
Combination Treatment 
In view of the mechanism of action of the alpha-adrenoceptor antagonists and the 5ARIs, the use of 
both classes of drug in combination is logical from a pharmacological point of view. Indeed, when 
these agents are used in combination, the immediate relief of symptoms offered by the alpha-
adrenoceptor antagonists and the long-term benefits in terms of reduction in prostate size and risk 
of both AUR and surgical intervention shown by the 5ARIs are beneficial. The combination of 
doxazosin and finasteride was shown to be significantly superior to either doxazosin or finasteride 
alone in the context of clinical progression of BPH, symptom score, maximum urinary flow rates or 
development of AUR and or the need for BPH related surgery.10 The combination of dutasteride and 
tamsulosin has also recently been investigated11. Results are similar with overall improvement seen 
with regard to symptoms, symptom score, reduced disease progression and a lower incidence of 
AUR and the need for surgical intervention. Combination therapy is of clear benefit for men with 
moderate to severe LUTS and large prostates estimated at over 30g.   
Monitoring in combination therapy should be as above, which was discussed for the individual 
agents. Patients who respond to combination therapy may discontinue the alpha-adrenoceptor 
antagonist after 6-9 months. The patient may then continue with monotherapy or if symptoms recur 
they should restart the combination therapy.  
Antimuscarinic Drugs 
Patients who present with BPH with a significant component of detrusor over activity may benefit 
from a combination of alpha-adrenoceptor antagonist and an antimuscarinic drug, such as 
oxybutynin. Clearly, this could become complex for patients who have a history of AUR and should 
be approached with care in such cases. Elderly patients with a history of cardiovascular disease or 
angle-closure glaucoma are also a risk when considering this combination of drugs. 
Herbal Treatments 
There are a number of herbal treatments available for the treatment of LUTS associated with BPH. 
Most contain the herbal extract Serenoa repens (Saw Palmetto). There is limited trial evidence in the 
literature to support such products and what does exist is conflicting in nature. Certainly the largest  
clinical trial to date that examined the use of Saw Palmetto did not give any convincing results, with 
all measurable aspects of BPH not improved when compared to placebo.12 At this time, due to the 
lack of good quality clinical evidence, it is difficult for health professionals to recommend such 
treatments for BPH.  
Surgical Intervention 
Many patients will ultimately require surgical intervention to control complications of LUTS. In the 
case of AUR patients present with painful retention of urine which needs to be relived immediately. 
It is resolved, in the short-term, with the introduction of a urinary catheter. Patients may also 
present with chronic retention where a painless but palpable bladder can develop over an extended 
period of time giving rise to the potential for renal failure, hypertension and chronic infection. Once 
catheterised, these patients may then suffer a significant loss of urine which could lead to electrolyte 
imbalance. In cases of both acute and chronic retention, patients are often referred for 
prostatectomy – clearly this is associated with risks and the potential to affect urinary continence 
and sexual function following the surgery. In the case of acute retention, emergency surgery may be 
required, which has significantly higher risks than elective surgery for chronic retention.5 
In some cases of AUR men may be selected for trial without catheter. In such cases, patients may be 
given alpha-adrenoceptor antagonists to improve the likelihood of voiding without surgical 
intervention.13, 14  
Other patients will require surgery due to the fact that medical treatment has failed or the patient 
has chosen to have the problem surgically corrected. The aim of surgical intervention is to remove 
the obstruction to the flow of urine or to solve complication associated with LUTS such as AUR, gross 
haematuria, renal failure or bladder calculi associated with BPH or BPH related obstruction. There 
are a number of surgical options: 
Transurethral resection of the prostate (TURP) 
This is the “gold standard” procedure and has improved dramatically in recent years in terms of the 
need to repeat the procedure as well as associated morbidity and mortality. The TURP involves using 
a diathermy current through a fine metal loop which effectively cuts away the offending tissue. The 
developments in the equipment used to perform the procedure have significantly enhanced the 
safety profile. There is a significant risk of blood loss during surgery and that may require a 
transfusion to correct the deficit. Patients can also suffer from TURP syndrome where an extended 
surgical period has resulted in patients absorbing excessive amounts of irrigation fluid and thus 
developing hyponatraemia.  Some men may experience impotence and incontinence but the risks 
are low, while others may develop retrograde ejaculation.15   
Transurethral incision of the prostate (TUIP) 
This procedure is primarily considered for men who are sexually active and wish to retain outward 
ejaculation. TURP has a significant rate of retrograde ejaculation with around 90% of men being 
affected, while , in contrast, only 15-30% will be affected after TUIP.15 This procedure involves a 
different type of incision and thus reduces the risk of ejaculatory dysfunction.  
 
 
Laser prostatectomy 
Various laser sources have proved useful in prostatic surgery. Holmium laser enucleation (HoLEP) 
has been compared to TURP and has shown positive outcomes in terms of immediate post-surgical 
and longer terms benefits.16 The benefit of this approach is clear in patients with larger prostates 
and also those who may be at increased bleeding risk, such as patients taking long-term 
anticoagulants or those who have bled profusely on catheterisation.   
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